Abcam (LON:ABC) Stock Price Passes Above Two Hundred Day Moving Average of $1,434.29

Shares of Abcam plc (LON:ABC) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 1,434.29 ($18.74) and traded as high as GBX 1,502 ($19.62). Abcam shares last traded at GBX 1,495 ($19.53), with a volume of 173,072 shares traded.

Several research firms have recently issued reports on ABC. Liberum Capital boosted their price target on shares of Abcam from GBX 1,400 ($18.29) to GBX 1,450 ($18.94) and gave the company a “hold” rating in a research report on Wednesday, August 4th. Berenberg Bank upped their target price on shares of Abcam from GBX 1,350 ($17.64) to GBX 1,400 ($18.29) and gave the stock a “hold” rating in a report on Tuesday, September 14th. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of GBX 1,442 ($18.84).

The company has a market cap of £3.41 billion and a PE ratio of 210.14. The stock’s 50 day moving average price is GBX 1,498.83 and its 200-day moving average price is GBX 1,434.84. The company has a debt-to-equity ratio of 17.41, a quick ratio of 4.08 and a current ratio of 4.78.

In other news, insider Alan Thomas Hirzel sold 6,138 shares of the company’s stock in a transaction on Thursday, September 23rd. The shares were sold at an average price of GBX 1,536 ($20.07), for a total value of £94,279.68 ($123,177.01).

About Abcam (LON:ABC)

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays.

See Also: What’s a Black Swan?

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.